ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

Phase 2

Alnylam Pharmaceuticals, Inc. (ALNY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in TTR-mediated Amyloidosis

View Full Landscape

Drug Information

Target Indication

TTR-mediated Amyloidosis

Clinical Trial

NCT01961921

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/27/2018

Onpattro

Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

OrphanAccelerated

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALNY

Alnylam Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

NucresiranPhase 3

Transthyretin Amyloidosis With Cardiomyopathy

VutrisiranPhase 3

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

LumasiranPhase 3

PH1

ZilebesiranPhase 3

Hypertension

patisiran (ALN-TTR02)Phase 3

TTR-mediated Amyloidosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts